BioStable Science & Engineering, a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, announced today the initial closing of its Series C equity financing.
BioStable Science & Engineering, Inc., a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, today announced that over 500 patients worldwide have now been treated using the HAART Aortic Annuloplasty Device.
The function of the HAART 300 Aortic Annuloplasty Device is to restore and maintain the normal three-dimensional shape of the aortic valve.
BioStable Science & Engineering Announces announced today the first commercial uses of the HAART 300 Aortic Annuloplasty Device in the U.S. by doctors at the West Virginia University (WVU) Heart and Vascular Institute in Morgantown, West Virginia. Dr. Lawrence Wei, Dr. Vinay Badhwar and Dr. J. Scott Rankin, were the collaborating surgeons for the procedures.
BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal annuloplasty device designed for aortic valve repair.